Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of SULGEN Spray Phleum pratense for grass pollen allergy
2021-002881-42Phase 2Completed
- Sponsor
- ROXALL Medizin GmbH
- Start
- Aug 2022
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SULGEN in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and grass pollen allergy (5 arms), sponsored by ROXALL Medizin GmbH. Primary endpoints: Percentage of patients with improved titrated nasal provocation test response and Change in number of dosing steps to positive tNPT response. Started Aug 2022; status: completed.
02
Drugs
SULGEN
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2021-002881-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002881-42.